Bone Marrow Transplantation https://doi.org/10.1038/s41409-019-0716-9 ARTICLE Agreements and uncertainties in autologous haematopoietic stem cell mobilization and collection. A Spanish consensus document J. L. Bueno 1 ● A. Alegre 2 ● O. López-Villar 3 ● S. Querol 4 ● J. L. Arroyo 5 ● R. Goterris 6 ● A. Sureda 7 ● J. M. García-Gala 8 ● C. Amunarriz 5 ● C. Albo 9 ● F. Fernández-Fuertes 10 ● L. Medina 4 ● M. L. Antelo 11 ● M. Blanquer 12 ● C. Vallejo 13 ● M. Canales 14 ● I. Vidales-Mancha 15 ● R. F. Duarte 1 Received: 1 August 2019 / Revised: 27 September 2019 / Accepted: 30 September 2019 © The Author(s), under exclusive licence to Springer Nature Limited 2019 Abstract Although many experts position statements on autologous stem cell mobilization have been published, there are some aspects that are still under discussion. A Spanish Hematologist expert group was summoned to settle on agreements and uncertainties on PBSCs mobilization, including factors not always considered; as apheresis and cytometry key factors that determine a successful PBSC collection. This document reviews critical factors that define poor mobilizer patients and the tools to better collect the desired stem cells for a successful autologous haematopoietic stem cell transplant. Introduction A successful PBSC mobilization using first line treatment protocols with rHuG-CSF alone and/or with chemotherapy is not reached in around 15% of the patients [1, 2]. A clear standard protocol for managing mobilization failures is not yet well stablished, although several consensus or guide- lines documents have been published [3–6]. In Spain, there is not a defined National Consensus Guide to treat these patients. In 2017–2018, Spanish hematologists formed a Working Party Group to define a National Consensus Protocol to approach mobilization failure management in hematologic patients. The group was founded on the following premises: 1. The particular focus of this consensus is to provide recommendations on the matter not addressed by previous guidelines. 2. A new and helpful approach would be to define what are the well-established agreements and uncertain areas on this matter, supported on the documents * J. L. Bueno Jolubuca1898@gmail.com 1 Hematology Department, Puerta de Hierro-Majadahonda Hospital, Madrid, Spain 2 Hematology Department, Universitary Hospital La Princesa & Universitary Hospital Quironsalud, Madrid, Spain 3 Transfusion Service, Hematology Department, University Hospital of Salamanca, Salamanca, Spain 4 Cell Therapy Services, Banc de Sang i Teixits, Barcelona, Spain 5 Cantabria Blood Transfusion Center, Fundación Marqués de Valdecilla, IDIVAL, Santander, Spain 6 Hematology and Hemotherapy Department, Clinic Universitary Hospital, Valencia, Spain 7 Hematology Department, Institut Català d’Oncologia-Hospitalet, IDIBELL, Barcelona, Spain 8 Hematology and Hemotherapy Department, Hospital Universitario Central de Asturias, Oviedo, Spain 9 Hematology Department, Alvaro Cunqueiro Hospital, Vigo, Spain 10 Hematology Departament, Complejo Hospitalario Universitario Insular Materno Infantil Las Palmas de Gran Canaria, Las Palmas, Spain 11 Transfusion Service, Hematology Department, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain 12 Hematology Cell Therapy Unit, IMIB-University Hospital Virgen de la Arrixaca, University of Murcia, Murcia, Spain 13 Hematopietic Transplant Program, University Hospital Donostia, San Sebastián, Spain 14 Hematology Department, Hospital La Paz, Madrid, Spain 15 Carlos-Haya Hospital, Málaga, Spain Supplementary information The online version of this article (https:// doi.org/10.1038/s41409-019-0716-9) contains supplementary material, which is available to authorized users. 1234567890();,: 1234567890();,: